Open session of the standing technical committee of the EUFMD- 2000

P.Kitching;T. Rendle and B. Newman Appendix 30 Comparison of FMDV neutralization tests using three different cell lines: validation of the new FAO reference sera P. Moonen; G.K.W. Miedema; F. van Hemert-Kluitenberg; G. Chenard and A. Dekker Appendix 31 Longevity of the antibody response in pigs and sheep following a single administration of high potency emergency FMD vaccines S.J. Cox and P.V. Barnett Appendix 32 Enhancement of the immune response induced by the inclusion of saponin in oil adjuvanted vaccines against foot-and-mouth disease E. Smitsaart; N. Mattion; J.L. Filippi; B. Robiolo; O. Periolo; J. La Torre and R.C. Bellinzoni Appendix 33 Experimental vaccination against FMDV with immunocomplexes H. Yadin; Dalia Chai; A. Bril; B. Gelman and M. Amadori Appendix 34 Formaldehyde enhances BEI-inactivation rates of foot-and-mouth disease (FMD) virus by at least a ten-fold Simon J. Barteling and Nazeem I. Cassim Appendix 35 Validating the efficacy of emergency foot-and-mouth disease vaccines in sheep following virus challenge using the non-structural polyprotein 3ABC MAT-ELISA Paul Barnett; Morag Forsyth and Sarah Cox Appendix 36 Experimental FMD infections in pigs: a possible design for a PD50 experiment Hanny Swam and Aldo Dekker Appendix 37 The second report of the European Pharmacopoeia Working Group. Present and future contacts with the European Pharmacopoeia and with EMEA Kris De Clercq (on behalf of the European Pharmacopoeia Working Group) Appendix 38 Preliminary results from the EUFMD Expert Elicitation Workshop on risk of introduction of FMD to Europe John Ryan and Lisa Gallagher Appendix 39 List of Participants